Unraveling the Dyslipidemic Landscape in Moyamoya Disease: O x LDL as a Key Biomarker
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70441 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Chaofan Zeng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Moyamoya Disease, Lipoproteins, LDL, Dyslipidemias. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Administration of Hospitals Incubating Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
The pathogenic mechanisms of moyamoya disease (MMD) remain unrecognized. Although genetic predisposition and hemodynamic changes have been focused on, emerging evidence suggests dyslipidemia may also contribute to MMD. Here, we performed a comprehensive analysis of lipid profiles, aiming to elucidate potential mechanisms in MMD.
Methods
In this prospective case–control study, 222 MMD patients and 231 healthy controls (HCs) were enrolled. The comprehensive lipid profiling was performed, encompassing standard lipids, apolipoproteins, oxidized low‐density lipoprotein (oxLDL), and small dense LDL (sdLDL). Statistical models of weighted quantile sum (WQS) and Bayesian kernel machine regression (BKMR) were applied to capture individual and joint lipid effects on MMD risk.
Results
Compared with HCs, MMD patients exhibited significantly higher oxLDL, sdLDL, and lipoprotein(a) ( p < 0.05). OxLDL emerged as a robust independent risk factor for MMD (adjusted OR 1.146, 95% CI 1.102–1.210, p < 0.001). WQS analysis further identified oxLDL as the single greatest contributor to MMD risk, with additional support from BKMR showing marked synergistic interactions between oxLDL and homocysteine.
Conclusions
The study revealed a comprehensive dyslipidemic landscape in MMD, highlighting oxLDL as a pivotal biomarker. The results underscored the significance of lipid metabolism in MMD pathogenesis, warranting further investigation to guide novel diagnostic and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.
- Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Neuropathology, Beijing Neurosurgical Institute, Beijing, China.
ORCID-Profile: Chaofan Zeng, Dong Zhang, Guojun Zhang, Jizong Zhao
Förderung
- Beijing Municipal Administration of Hospitals Incubating Program
- National Natural Science Foundation of China
Zitieren
APA
Zeng, C., Chen, H., Liu, J., Bao, Y., Sun, X., Meng, F., Xue, Y., Cui, Y., Zhao, Q., Zhang, J., Li, H., Zhang, D., Wang, R., Zhang, Y., Zhang, G., Zhao, J., & Zhang, Q. (2025). Unraveling the Dyslipidemic Landscape in Moyamoya Disease: O x LDL as a Key Biomarker. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70441
Vancouver
Zeng C, Chen H, Liu J, Bao Y, Sun X, Meng F, et al. Unraveling the Dyslipidemic Landscape in Moyamoya Disease: O x LDL as a Key Biomarker. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70441
BibTeX
@article{Zeng2025,
author = {Zeng, Chaofan and Chen, Haoyuan and Liu, Jie and Bao, Youyuan and Sun, Xudong and Meng, Fanbo and Xue, Yimeng and Cui, Yunhao and Zhao, Qianjun and Zhang, Jing and Li, Hao and Zhang, Dong and Wang, Rong and Zhang, Yan and Zhang, Guojun and Zhao, Jizong and Zhang, Qian},
title = {Unraveling the Dyslipidemic Landscape in Moyamoya Disease: O x LDL as a Key Biomarker},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70441}
}
EUVIMED